Medical Device Recalls and Adverse Event Reporting in Thailand

When a medical device malfunctions in the field, or a manufacturer somewhere in the world issues a global safety notice, the clock starts running in Thailand whether or not anyone at head office has thought about it yet. Thai FDA's vigilance system, built under the Medical Device Act B.E. 2562 (2019) and its implementing notifications, sets firm reporting timelines for adverse events, Field Safety Corrective Actions, and recall execution, and the Local License Holder (LLH), as the entity holding the Thai FDA certificate of registration, carries the responsibility regardless of where the triggering event actually happened. Thailand's framework tracks the IMDRF (International Medical Device Regulators Forum) guidelines that most major regulators have adopted as a common baseline, which makes it broadly familiar to companies with existing vigilance systems elsewhere, but the specific Thai deadlines still have to be built into the operation.

The LLH Cannot Outsource Vigilance to the Manufacturer

The LLH is on the hook for the full vigilance lifecycle in Thailand: receiving adverse event and device deficiency reports from healthcare facilities and users, running the initial investigation and assessment, reporting to Thai FDA within the required windows, executing Field Safety Corrective Actions when needed, and managing recalls. None of that can be handed off entirely to an overseas manufacturer without the LLH maintaining its own Thai FDA-facing reporting capability. Post-market surveillance, the broader collection and evaluation of post-market data as a signal-detection activity, runs alongside this incident-reporting obligation rather than replacing it, and the two systems need to function together as part of the same quality management system rather than as separate compliance exercises.

What Counts as a Reportable Adverse Event, and How Fast

Thai FDA distinguishes reportable adverse events primarily by severity and by how directly the device is implicated. An event leading to, or that could have led to, serious injury or death, where there is a reasonable possibility the device caused or contributed to the outcome, must reach Thai FDA within 10 working days of the LLH or manufacturer becoming aware of it. That same 10-working-day clock applies to unanticipated serious adverse device effects: outcomes not described in the IFU or risk management documentation at the time of registration, which matter because they can signal a systematic device failure rather than user error or a patient-specific factor. A third category, device deficiencies that could have led to serious injury or death had they reached clinical use, is reportable even without an actual adverse outcome; this near-miss category exists precisely to surface systemic quality problems before they reach a patient. Thai FDA does allow periodic summary reporting for certain device types and event categories in place of individual case reports, but only where the LLH and Thai FDA have explicitly agreed to it. Treating events as summary-reportable on the LLH's own judgment, without that agreement, is itself a compliance violation.

Field Safety Corrective Actions Have Their Own Notification Clock

A Field Safety Corrective Action, or FSCA, is any action taken to reduce a risk of death or serious injury tied to a device already in distribution, whether that action is a recall, a device or software update, an IFU change, or a Field Safety Notice advising facilities and users of interim precautions. The LLH must notify Thai FDA before starting an FSCA that originates in Thailand, or immediately if the FSCA was triggered by events elsewhere but affects devices distributed in Thailand. That notification has to describe the risk, identify the affected devices by model, serial or lot number, and quantity distributed, and lay out the proposed action and its timeline. Thai FDA responds with a Field Safety Notice reference number, and the LLH then has to distribute that notice to every healthcare facility and distributor holding affected devices within a Thai FDA-specified window, typically 48 to 72 hours for serious risks, with documented distribution and confirmed receipt retained on file.

Recall Classification Sets the Pace of Everything Else

Thai FDA classifies recalls using a risk-based system aligned with IMDRF practice, and the classification determines how fast everything downstream has to move. Thai FDA's own recall guidance sets recall risk levels 1 through 3, based on a health-hazard evaluation, rather than a tiered Class I/II/III notification-speed system. A Level 1 recall, where the device presents a reasonable probability of severe, life-threatening, or fatal harm, requires the recall report (Form R.M.P. 3) to reach Thai FDA within 48 hours of the LLH determining a recall is necessary. Level 2 recalls, involving possible temporary or reversible harm, and Level 3 recalls, where health impact is not likely, share the same 5-business-day window for that report; Thai FDA does not give Level 3 a less compressed timeline than Level 2, the two are identical on this point. Separately, Field Safety Notice distribution to all affected parties must begin within 48 hours of the recall being confirmed regardless of level, and if a public alert is warranted it must go out within 24 hours of Thai FDA's approval of the alert. Once a recall closes, the LLH must submit a recall effectiveness check confirming what percentage of affected devices were recovered, followed by a final report covering root cause analysis, corrective and preventive actions, and the effectiveness check outcome, within the timeframe Thai FDA specified at the recall's opening.

When the Trigger Comes From Outside Thailand

Global FSCAs are where distribution traceability gets tested. When a manufacturer initiates an FSCA elsewhere for a device also registered in Thailand, the LLH has to assess whether Thai product is affected and report that assessment to Thai FDA. If it is affected, the LLH runs an FSCA in Thailand consistent with the global action; if it is not, because the affected lots were never distributed to Thailand, the LLH still has to give Thai FDA a documented explanation for why Thai product falls outside the global action's scope. Either way, the LLH's ability to respond fast enough depends entirely on the quality of its distribution records. If affected devices cannot be traced to individual healthcare facilities within the required timeframe, the FSCA cannot be executed properly, and Thai FDA treats that as a failure of the recall management system in its own right, a separate finding from the underlying safety issue itself.

Why Vigilance Readiness Cannot Wait for the First Incident

The quality of an LLH's vigilance response is set long before any adverse event report arrives. An intake process capable of capturing a report the moment it reaches a call center or a hospital contact, an assessment protocol that consistently applies the severity criteria above rather than guessing case by case, and a reporting system already wired to Thai FDA's expected format all have to exist before the first serious injury report lands, not after. Building this reactively, once an event is already in motion, routinely costs the LLH the working days it needed to meet the 10-day reporting window. The same is true of distribution traceability: an LLH that only discovers its record-keeping gaps when a global FSCA lands on its desk has already lost the ability to respond within Thai FDA's expected timeframe, and that failure gets treated as a compliance issue in its own right, independent of the underlying device safety concern.

A vigilance event handled correctly, with timely Thai FDA notification and a complete field action, protects both the device's registration and the LLH's standing with the regulator. DeeMED Consulting works with foreign manufacturers on the registration and post-market obligations that vigilance sits on top of, including Thai FDA medical device registration and CSDT preparation that builds a functioning post-market surveillance system into the dossier from the start rather than as an afterthought.